EMEA-001664-PIP02-15-M04
Key facts
Invented name |
Aimovig
|
Active substance |
erenumab
|
Therapeutic area |
Neurology
|
Decision number |
P/0107/2019
|
PIP number |
EMEA-001664-PIP02-15-M04
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
Prevention of migraine headaches
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Novartis Europharm Limited
Tel. +41 6132 41111 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|